FDA< KT-333

Kymera receives FDA fast track designation for KT-333
Pharmaceutical Business Review
Tue, 09/19/23 - 10:42 am
Kymera Therapeutics
fast track
FDA< KT-333
cutaneous T-cell lymphoma